Cortisol and cortisone analysis in serum and plasma by atmospheric pressure photoionization tandem mass spectrometry

Clinical Biochemistry

Volumn 37, Issue 5, 2004, Pages 357-362

  Kushnir, Mark M ^a   Neilson, Rebecca ^a   Roberts, William L ^b   Rockwood, Alan L ^a  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

11 hydroxysteroid dehydrogenase; Atmospheric pressure photoionization; Cortisol; Cortisone; Cushing's disease; Mass spectrometry

Indexed keywords

CORTISONE; HYDROCORTISONE; TERT BUTYL METHYL ETHER;

ADULT; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; EVAPORATION; EXTRACTION; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; IONIZATION; NORMAL HUMAN; PHOTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; TANDEM MASS SPECTROMETRY;

11-BETA-HYDROXYSTEROID DEHYDROGENASES; ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORTISONE; HUMANS; HYDROCORTISONE; ISOENZYMES; MASS SPECTROMETRY; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS;

EID: 1842861774     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2004.01.005     Document Type: Article

References (24)

1. Tiosano D., Eisentein I., Militianu D., Chrousos G.P., Hochberg Z. 11β-hydroxysteroid dehydrogenase activity in hypothalamic obesity. J. Clin. Endocrinol. Metab. 88:2003;379-384.
2. Stewart P.M. 11β-hydroxysteroid dehydrogenase: implications for clinical medicine. Clin. Endocrinol. (Oxford). 44:1996;493-499.
3. Bujalska I.J., Kumar S., Stewart P.M. Does central obesity reflect "Cushing's disease of the omentum"? Lancet. 349:1997;1210-1213.
4. Stewart P.M., Boulton A., Kumar S., Clark P.M., Shackleton C.H.L. Cortisol metabolism in human obesity: impaired cortisone→cortisol conversion in subjects with central adiposity. J. Clin. Endocrinol. Metab. 84:1999;1022-1027.
5. Reinke M. Subclinical Cushing's syndrome. Endocrinol. Metab. Clin. North Am. 29:2000;43-56.
6. Andrews R.C., Herlihy O., Livingstone D.E.W., Andrew R., Walker B.R. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. J. Clin. Endocrinol. Metab. 87:2002;5587-5593.
7. Andrews R.C., Walker B.R. Glucocorticoids and insulin resistance: old hormones, new targets. Clin. Sci. 96:1999;513-523.
8. Phillips D.I.W., Barker D.J.P., Fall C.H.D.et al. Elevated plasma cortisol concentrations: an explanation for the relationship between low birth weight and adult cardiovascular risk factors. J. Clin. Endocrinol. Metab. 83:1998;757-760.
9. Palermo M., Delitala G., Mantero F., Stewart P.M., Shackleton C.H.L. Congenital deficiency of 11β-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): diagnostic value of urinary free cortisol and cortisone. J. Endocrinol. Invest. 24:2001;17-23.
10. Shimojo M., Stewart P.M. Apparent mineralocorticoid excess syndrome. J. Endocrinol. Invest. 51:1995;518-532.
11. Stewart P.M., Wallace A.M., Valentino R., Burt D., Shackleton C.H.L., Edwards C.R.W. Mineralocorticoid activity of licorice: 11β-hydroxysteroid dehydrogenase comes of age. Lancet. 2:1987;821-824.
12. Edwards C.R.W., Walker B.R., Benediktsson R., Seckl J.R. Congenital and acquired syndrome of apparent mineralocorticoid excess. J. Steroid Biochem. Mol. Biol. 45:1983;1-5.
13. Mune T., Morita H., Suzuki T.et al. Role of local 11β-hydroxysteroid dehydrogenase type 2 expression in determining the phenotype of adrenal adenomas. J. Clin. Endocrinol. Metab. 88:2003;864-870.
14. Funder J.W., Pearce P.T., Smith R., Smith A.I. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 242:1988;583-585.
15. White P.C., Mune T., Agarwal A.K. 11β-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr. Rev. 18:1997;135-156.
16. Tello F.L., Hernandez D.M. Performance evaluation of nine hormone assays on the Immulite 2000 immunoassay system. Clin. Chem. Lab. Med. 38:2000;1039-1042.
17. Murphy B.E.P. Lack of specificity of urinary free cortisol determinations: why does it continue? J. Clin. Endocrinol. Metab. 884:1999;2258-2259.
18. Murphy B.E.P. How much "UFC" is really cortisol? Clin. Chem. 46(6):2000;793-794.
19. Vogeser M., Zachoval R., Felbinger T.W., Jacob K. Increased ratio of serum cortisol to cortisone in acute-phase response. Horm. Res. 15:2002;269-278.
20. Taylor R.L., Machacek D., Singh R.J. Validation of a high-throughput liquid chromatography-tandem mass spectrometry method for urinary cortisol and cortisone. Clin. Chem. 48:2002;1511-1519.
21. Kushnir M.M., Rockwood A.L., Nelson G.N., Terry A.H., Meikle A.W. Analysis of cortisol in urine by LC-MS/MS. Clin. Chem. 49:2003;965-967.
22. Robb D.B., Covey T.R., Bruins A.P. Atmospheric pressure photoionization: an ionization method for liquid chromatography-mass spectrometry. Anal. Chem. 72:2000;3653-3659.
23. Meikle A.W., Findling J., Kushnir M.M., Rockwood A.L., Nelson G.J., Terry A.H. Pseudocushings syndrome cause by interference of drug Fenofibrate with HPLC assay for cortisol. J. Clin. Endocrinol. Metab. 88:2003;3521-3524.
24. Annesley T.M. Ion suppression in mass spectrometry. Clin. Chem. 49:2003;1041-1044.